- 09.10.2014
October 9, 2014. The Group of the Companies R-PHARM and “Kyorin Pharmaceutical” , with assistance of Taishi Group of Companies, have reached a basic agreement for activities in Russia and neighboring nations related to the development and marketing of Imidafenacin, a treatment for overactive bladder (OAB) that was discovered and developed by Kyorin Pharmaceutical.
Under the terms of this agreement, Kyorin Pharmaceutical grants R-Pharm exclusive rights to activities related to the development and marketing of Imidafenacin in Russia and neighboring nations.
Imidafenacin is a novel anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB. Imidafenacin selectively acts on the bladder, and therefore incidence of dry mouth is rather small. In Japan, Kyorin Pharmaceutical and Ono Pharmaceutical Co.,Ltd launched Imidafenacin under the brand names Uritos® 0.1mg tablets and Staybla® 0.1mg tablets respectively in June 2007. An additional dosage form as an Orally Disintegrating (OD) tablet was launched in April 2011.
While Kyorin Pharmaceutical has achieved early market penetration in Japan and contributed to the QOL of patients suffering from symptoms of OAB, it aims to popularize Imidafenacin in the Russian market and promote its global business through this agreement with R-Pharm.
The companies expect the impact that the conclusion of this agreement on consolidated financial forecasts for the fiscal year ending March 31 2015 to be negligible.